Safety and efficacy of recombinant activated factor VII for refractory hemorrhage in pediatric patients on extracorporeal membrane oxygenation: A single center review

Perfusion (United Kingdom)

Volumn 29, Issue 2, 2014, Pages 163-170

  Long, M T ^a   Wagner, D ^b   Maslach Hubbard, A ^c   Pasko, D A ^b   Baldridge, P ^d   Annich, G M ^d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

ECMO; extracorporeal membrane oxygenation; hemorrhage; hemostasis; NovoSeven; pediatrics; recombinant activated Factor VIIa; rFVIIa

Indexed keywords

ALBUMIN; AMINOCAPROIC ACID; APROTININ; FIBRINOGEN; FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADOLESCENT; ADULT RESPIRATORY DISTRESS SYNDROME; ATRIOVENTRICULAR SEPTAL DEFECT; BLEEDING; CELIAC ARTERY; CELIAC ARTERY STENOSIS; CELIAC DISEASE; CHILD; CHILD DEATH; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; CLINICAL ARTICLE; CONGENITAL DIAPHRAGM HERNIA; CONTROLLED STUDY; CRYOPRECIPITATE; DIGEORGE SYNDROME; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE CONCENTRATE; EXTRACORPOREAL MEMBRANE OXYGENATION DEVICE; EXTRACORPOREAL OXYGENATION; FALLOT TETRALOGY; HEART RIGHT VENTRICLE DOUBLE OUTLET; HEMOSTASIS; HUMAN; HYPOPLASTIC LEFT HEART SYNDROME; IATROGENIC DISEASE; INFANT; MEDICAL RECORD REVIEW; PATIENT SAFETY; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PULMONARY VALVE ATRESIA; REFRACTORY HEMORRHAGE; RETROSPECTIVE STUDY; REVIEW; SCHOOL CHILD; SEPSIS; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOSIS; BLOOD CLOT; DEVICE FAILURE; ERYTHROCYTE TRANSFUSION; MEMBRANE OXYGENATOR; MORTALITY; SURVIVAL RATE;

ECMO; EXTRACORPOREAL MEMBRANE OXYGENATION; HEMORRHAGE; HEMOSTASIS; NOVOSEVEN; PEDIATRICS; RECOMBINANT-ACTIVATED FACTOR VIIA; RFVIIA;

ADOLESCENT; BLOOD COMPONENT TRANSFUSION; CHILD, PRESCHOOL; EXTRACORPOREAL MEMBRANE OXYGENATION; FACTOR VIIA; FEMALE; HEALTH RECORDS, PERSONAL; HEMORRHAGE; HUMANS; INFANT; MALE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES;

EID: 84896872576     PISSN: 02676591     EISSN: 1477111X     Source Type: Journal    
DOI: 10.1177/0267659113499782     Document Type: Review

References (50)

1. Ayad O, Dietrich A, Mihalov L. Extracorporeal membrane oxygenation. Emerg Med Clinic North Am. 2008 ; 26: 953-959
2. Brogan TV, Thiagarajan RR, Rycus PT, et al. Extracorporeal membrane oxygenation in adults with severe respiratory failure: a multi-center database. Intensive Care Med. 2009 ; 35: 2105-2114
3. Gaffney AM, Wildhirt SM, Griffin MJ, et al. Extracorporeal life support. BMJ. 2010 ; 341: 982-986
4. Oliver WC. Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth. 2009 ; 13: 154-175
5. Acharya S Manual of Pediatric Hematology and Oncology. 5 th ed.Oxford: Elsevier, 2011, pp.378-383. Lanzkowsky P, ed. Oxford: Elsevier ; 2011: 378-383.
6. Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost. 1999 ; 82: 531-539
7. Aitken MG. Recombinant factor VIIa. Emerg Med Australas. 2004 ; 16: 446-455
8. Cate HT, Bauer KA, Levi M, et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest. 1993 ; 92: 1207-1212
9. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood. 2004 ; 104: 3858-3864
10. Weiskopf RB. Recombinant-activated coagulation factor VII (NovoSeven®): current development. Vox Sang. 2007 ; 92: 281-288
11. Princeton, NJ: Novo Nordisk Inc ; 2008 :
12. Alten JA, Benner K, Green K, et al. Pediatric off-label use of recombinant factor VIIa. Pediatrics. 2009 ; 123: 1066-1072
13. McQuilten ZK, Barnes C, Zatta A, et al. Off-label use of recombinant factor VIIa in pediatric patients. Pediatrics. 2012 ; 129: e1533-1540
14. Shander A, Goodnough LT, Ratko T, et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven®) therapy. Pharm Ther. 2005 ; 30: 644-658
15. Yank V, Tuohy CV, Logan AC, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med. 2011 ; 154: 529-540
16. Guzzetta NA, Huch S, Fernandez JD, et al. Use of recombinant factor VIIa for uncontrolled bleeding in neonates after cardiopulmonary bypass. Paediatr Anaesth. 2009 ; 19: 364-370
17. Simpson E, Lin Y, Stanworth S, et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev. 2012 ; 3: CD005011
18. Brose S, Sirbu H, Engel M, et al. Successful use of recombinant factor VIIa in a patient with intractable bleeding during extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg. 2005 ; 53: 389-390
19. Bui JD, Despotis GD, Trulock EP, et al. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg. 2002 ; 124: 852-854
20. Dominguez TE, Mitchell M, Friess SH, et al. Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2005 ; 6: 348-351
21. Dunne B, Xiao P, Andrews D. Successful use of factor VIIa to control life-threatening post-operative haemorrhage in a patient on extra-corporeal membrane oxygenation. Heart Lung Circ. 2012 ; 21: 229-230
22. Niebler RA, Punzalan RC, Marchan M, et al. Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2010 ; 11: 98-102
23. Olbrich P, Parilla JP, Eraso CC, et al. Combined use of recombinant activated factor VII and ECMO in severe postoperative bleeding after cardiac surgery in a newborn: death due to ventricular dysfunction. Klin Padiatr. 2012 ; 224: 193-194
24. Preston TJ, Olshove VF, Ayad O, et al. Novoseven use in a non-cardiac pediatric ECMO patient with uncontrolled bleeding. J Extra Corpor Technol. 2008 ; 40: 123-126
25. Repesse X, Ming Au S, Brechot N, et al. Recombinant factor VIIa for uncontrolled bleeding in patients with extracorporeal membrane oxygenation: report on 15 cases and literature review. Crit Care. 2013 ; 17: R55
26. Verrickt A, Proulx F, Morneau S, Vobecky S. Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth. 2004 ; 127: 1812-1813
27. Walker A, Davidson M, Chalmers E. Use of activated recombinant factor VII in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2010 ; 11: 537-538
28. Wittenstein B, Ng C, Ravn H, Goldman A. Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. Pediatr Crit Care Med. 2005 ; 6: 473-476
29. Hsia CC, Zurawska JH, Tong MZ, Eckert K, McAlister VC, Chin-Yee IH. Recombinant activated factor VII in the treatment of non-haemophilia patients: physician under-reporting of thromboembolic adverse events. Transfus Med. 2009 ; 19: 43-49
30. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006 ; 295: 293-298
31. Chapman AJ, Blount AL, Davis AT, Hooker RL. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery. Eur J Cardiothorac Surg. 2011 ; 40: 1314-1319
32. Karcouti K, Beattie S, Arellano R, et al. Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. Circulation. 2008 ; 118: 331-338
33. Riccabona M, Kuttnig-Haim M, Dacar D, et al. Venous thrombosis in and after extracorporeal membrane oxygenation: detection and follow-up by color Doppler sonography. Eur Rad. 1997 ; 7: 1383-1386
34. Rastan AJ, Lachmann N, Walther T, et al. Autopsy findings in patients on postcardiotomy extracorporeal membrane oxygenation (ECMO). Int J Artif Organs. 2006 ; 29: 1121-1131
35. Kojima S. Low-density lipoprotein apheresis and changes in plasma components. Ther Apher. 2001 ; 5: 232-238
36. Agarwal HS, Bennett JE, Churchwell KB, et al. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg. 2007 ; 84: 161-169
37. Apostolidou I, Sweeney MF, Missov E, et al. Acute left atrial thrombus after recombinant factor VIIa administration during left ventricular assist device implantation in a patient with heparin-induced thrombocytopenia. Anesth Analg. 2008 ; 106: 404-408
38. Chalwin RP, Tiruvoipati R, Peek GJ. Fatal thrombosis with activated factor VII in a paediatric patient on extracorporeal membrane oxygenation. Eur J Cardiothorac Surg. 2008 ; 34: 685-686
39. Lucey MA and, Myburgh JA. Recombinant activated factor VII for exsanguinating haemorrhage post bilateral lung transplantation for extra-corporeal lung support-dependent respiratory failure. Anaesth Intensive Care. 2003 ; 31: 465-469
40. Swaminathan M, Shaw AD, Greenfield RA, Grichnik KP. Fatal thrombosis after factor VII administration during extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth. 2008 ; 22: 259-260
41. Syburra T, Lachat M, Genoni M, Wilhelm MJ. Fatal outcome of recombinant factor VIIa in heart transplantation with extracorporeal membrane oxygenation. Ann Thorac Surg. 2010 ; 89: 1643-1645
42. Veldman A, Neuhaeuser C, Akintuerk H, et al. rFVIIa in the treatment of persistent hemorrhage in pediatric patients on ECMO following surgery for congenital heart disease. Paediatr Anaesth. 2007 ; 17: 1176-1181
43. Velik-Salchner C, Sergi C, Fries D, et al. Use of recombinant factor VIIa (Novoseven®) in combination with other coagulation products led to a thrombotic occlusion of the truncus brachiocephalicus in a neonate supported by extracorporeal membrane oxygenation. Anesth Analg. 2005 ; 101: 924
44. Vincent JL, Rossaint R, Riou B, et al. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding - a European perspective. Crit Care. 2006 ; 10: R120
45. Warren OJ, Rogers PLB, Watret AL, et al. Defining the role of recombinant activated factor VII in pediatric cardiac surgery: where should we go from here?. Pediatr Crit Care Med. 2009 ; 10: 572-582
46. Meng ZH, Wolberg AS, Monroe DM, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma. 2003 ; 55: 886-891
47. Hacquard M, Durand M, Lecompte T, et al. Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centres (2005-7). Eur J Cardiothorac Surg. 2011 ; 40: 1320-1327
48. Masud F, Bostan F, Chi E, et al. Recombinant factor VIIa treatment of severe bleeding in cardiac surgery patients: a retrospective analysis of dosing, efficacy, and safety outcomes. J Cardiothorac Vasc Anesth. 2009 ; 23: 28-33
49. Willis C, Bird R, Mullany D, et al. Use of rFVIIa for critical bleeding in cardiac surgery: dose variation and patient outcomes. Vox Sang. 2010 ; 98: 531-537
50. Okanta KE, Edwin F, Falase B. Is recombinant activated factor VII effective in the treatment of excessive bleeding after paediatric cardiac surgery?. Interact Cardiovasc Thorac Surg. 2012 ; 15: 690-695